Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market

The Middle East & Africa circulating tumor cell (CTC) diagnostics market is expected to reach US$ 131.3 million by 2028 from US$ 75.3 million in 2021; it is estimated to grow at a CAGR of 8.3% during 2021–2028.

A circulating tumor cell is shed into the vasculature from the primary tumor and is carried around the body with the help of blood circulation. These circulating tumor cells are an indication of metastatic disease, and their detection can help in diagnosing the disease in its early stages and designing an appropriate treatment regime for the patient. In recent years, there have been significant advancements in isolation methods of circulating tumor cells for diagnosis. Immunoaffinity, physical properties, and direct analysis are among a few of the approaches used for circulating tumor cell isolation. Immunoaffinity is the affinity reactions that capture antibodies and target antigens present on cells of interest using magnetic beads, microfluidic flow, nanostructured substrate, microtubes, and leucocyte depletion. The microtube approach uses the biomimetic approach to stimulate the procedure of selectin-mediated cell adhesion for capturing CTCs. Even at a high flow rate of 4.8 ml/h, selectin-coated microtubes induce cell attachment and rolling, which promotes CTC binding with anti-EpCAM (i.e., epithelial cell adhesion molecule) and anti-PSMA antibodies. The device had a capture efficiency of 50% and an average purity of 66%, and it detected circulating tumor cells in 14 of 14 patient blood samples examined, compared to 9 of 14 detected by the CellSearch system. Physical properties are also used to isolate circulating tumor cells from peripheral blood cells. A few of the common physical properties used for the isolation of CTCs are density gradient centrifugation, microfiltration, microfluidics, and dielectrophoresis. Thus, the ongoing developments and advancements in various isolation techniques for circulating tumor cells are expected to gain traction in the coming years.

During the COVID19 pandemic, healthcare providers had to reduce the number of diagnostic services and screening programs to redirect their efforts on the management of this disease. As a result, cancer patients became more susceptible to serious infections and faced issues such as interrupted cancer or standard medical care. Increased pressure from elevated hospitalization rates for COVID-19 patients led to the reprofiling of many hospitals and departments, including oncology clinics, to treat COVID-19 patients. These factors harmed the progress of the Middle East and Africa circulating tumor cell (CTC) diagnostics market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the circulating tumor cell (CTC) diagnostics market. The Middle East & Africa circulating tumor cell (CTC) diagnostics market is expected to grow at a good CAGR during the forecast period.

Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Market Segmentation         

By Technology

• CTC detection and Enrichment Method
• CTC Direct Detection Methods
• CTC Analysis

By Application

• Clinical/Liquid Biopsy
  • Risk Assessment
  • Screening and Monitoring
• Research
  • Cancer Stem Cell and Tumorigenesis Research
  • Drug/Therapy Development

By End-User

• Hospitals and Clinics
• Research and Academic Institutes
• Diagnostic Centers

By Country

• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Companies Mentioned

• Thermo Fisher Scientific Inc.
• Stemcell Technologies Inc.
• Qiagen
• Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation)
• Fluxion Bioscience

Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Strategic Insights

Strategic insights for the Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Report Scope

Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Regional Insights

The geographic scope of the Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.